Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Bladder Cancer, January 2025 Free Subscription Abstracts Retrieve all available abstracts of the following 190 articles: HTML format

Single Articles

1. GONG Y, Zhang X, Xia YF, Cheng Y, et al
   A foundation model with weak experiential guidance in detecting muscle invasive bladder cancer on MRI.
   Cancer Lett. 2025 Jan 2:217438. doi: 10.1016/j.canlet.2025.217438.
   PubMed    
   Abstract available
   
   

2. NAGUMO Y, Hattori K, Kimura T, Sekino Y, et al
   Combined molecular subclass and immune phenotype correlate to atezolizumab plus radiation therapy response in invasive bladder cancer: BPT-ART Phase II study.
   Int J Radiat Oncol Biol Phys. 2025 Jan 2:S0360-3016(24)03774.
   PubMed    
   Abstract available
   
   

3. HIGAZY A, Elsawy A, Lofty A, Abdallah HM, et al
   Neutrophils to lymphocytes ratio as a predictor of BCG response in non-muscle invasive bladder cancer.
   Urologia. 2025 Jan 3:3915603241308974. doi: 10.1177/03915603241308974.
   PubMed    
   Abstract available
   
   

4. PRIP F, Lamy P, Lindskrog SV, Strandgaard T, et al
   Comprehensive genomic characterization of early-stage bladder cancer.
   Nat Genet. 2025 Jan 3. doi: 10.1038/s41588-024-02030.
   PubMed    
   Abstract available
   
   

5. DE JONG FC, Kvikstad V, Hoedemaeker RF, van der Made ACJ, et al
   PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.
   World J Urol. 2025;43:57.
   PubMed    
   Abstract available
   
   

6. CHEN L, Xu Q, Chen W, Liu J, et al
   Tumor-colonizing Lachnoclostridium-mediated chemokine expression enhances the immune infiltration of bladder urothelial carcinoma.
   Cancer Immunol Immunother. 2025;74:62.
   PubMed    
   Abstract available
   
   

7. LI Y, Zhang L, Xu G, Xu G, et al
   Exploration and validation of a novel reactive oxygen species-related signature for predicting the prognosis and chemotherapy response of patients with bladder cancer.
   Front Immunol. 2024;15:1493528.
   PubMed    
   Abstract available
   
   

8. FUKUHARA H, Hamada Y, Shimasaki S, Iga R, et al
   Initial experience of 980-nm diode laser treatment for recurrent non-muscle-invasive bladder cancer.
   IJU Case Rep. 2024;8:41-43.
   PubMed    
   Abstract available
   
   

9. HAUGNES HS, Kjaeve H, Bjerkaas E, Hellesnes R, et al
   Real-world data on utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer: impact on surgical complications and oncological efficacy.
   Acta Oncol. 2025;64:13-21.
   PubMed    
   Abstract available
   
   

10. RAZZAGHDOUST A, Jafari A, Mahdavi A, Mofid B, et al
    Diffusion-weighted MRI-Derived ADC and tumor volume as predictive imaging markers for neoadjuvant chemotherapy response in muscle-invasive bladder cancer.
    BMC Med Imaging. 2025;25:3.
    PubMed    
    Abstract available
    
    

11. CHEN L, Xu L, Zhang X, Zhang J, et al
    Diagnostic value of dual-layer spectral detector CT parameters for differentiating high- from low-grade bladder cancer.
    Insights Imaging. 2025;16:6.
    PubMed    
    Abstract available
    
    

12. ARITA Y, Kwee TC, Akin O, Shigeta K, et al
    Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer.
    Insights Imaging. 2025;16:7.
    PubMed    
    Abstract available
    
    

13. FENG X, Zhang Z, Mao S
    Prognostic and clinicopathological value of C-reactive protein in patients with bladder cancer: a meta-analysis.
    Ann Med. 2025;57:2445781.
    PubMed    
    Abstract available
    
    

14. LIN F, Zheng WC, Ke ZB, Chen DN, et al
    A comprehensive analysis-based study of Di-(2-ethylhexyl) phthalate (DEHP)-Environmental explanation of bladder cancer progression.
    Environ Pollut. 2024;367:125625.
    PubMed    
    Abstract available
    
    

15. REINHOLD A, Glasow A, Nurnberger S, Weimann A, et al
    Ionizing radiation and photodynamic therapy led to multimodal tumor cell death, synergistic cytotoxicity and immune cell invasion in human bladder cancer organoids.
    Photodiagnosis Photodyn Ther. 2024 Dec 31:104459.
    PubMed    
    Abstract available
    
    

16. MOVSISYAN VERNON AS, Fejerman L, Hoch JS, Keegan TH, et al
    Stage at diagnosis and cancer-specific survival for stomach, lung, colorectal, and bladder cancers among Armenians in California.
    Prev Med. 2024 Dec 31:108214. doi: 10.1016/j.ypmed.2024.108214.
    PubMed    
    Abstract available
    
    

17. BEAS-LOZANO EL, Remolina-Bonilla YA, Caballero R, Sobrevilla-Moreno N, et al
    Treatment Patterns for Metastatic Urothelial Carcinoma Across Eight Mexican Centers: The ALEBRIJE Study.
    JCO Glob Oncol. 2025;11:e2400431.
    PubMed    
    Abstract available
    
    

18. ZHANG Z, Xiao W, Wang Y, Zhang W, et al
    Exploring the potential of the combined diagnostic model of ADC value and bp-MRI VI-RADS in the evaluation of muscle invasion in bladder Cancer.
    Abdom Radiol (NY). 2025 Jan 2. doi: 10.1007/s00261-024-04788.
    PubMed    
    Abstract available
    
    

19. NING W, Chang P, Zheng J, Chen W, et al
    Toripalimab plus chemotherapy for metastatic muscle-invasive bladder cancer with a high tumor proportion score: a case report.
    Front Immunol. 2024;15:1485744.
    PubMed    
    Abstract available
    
    

20. ZHAO X, Yu X, Li W, Wang L, et al
    Prognostic Significance of CCDC8 in Bladder Cancer: Insights from Bioinformatics and Immunohistochemical Analysis.
    J Cancer. 2025;16:382-397.
    PubMed    
    Abstract available
    
    

21. SUZUKI T, Sato T, Sukhbaatar A, Sakamoto M, et al
    Ultrasound irradiation in the presence of microbubbles may enhance the antitumor effect of chemotherapeutic agents against bladder cancer.
    J Cancer. 2025;16:368-381.
    PubMed    
    Abstract available
    
    

22. TANG Z, Qian Y, Wang N, Chen Y, et al
    HPV-Associated Gene Signatures in Bladder Cancer: A Comprehensive Prognostic Model and its Implications in Immunotherapy.
    Int J Med Sci. 2025;22:140-157.
    PubMed    
    Abstract available
    
    

23. CHU C, Fu Y, Yang J, Fan X, et al
    Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer.
    Front Oncol. 2024;14:1437006.
    PubMed    
    Abstract available
    
    

24. ZHAN Y, Weng M, Guo Y, Lv D, et al
    Identification and validation of the nicotine metabolism-related signature of bladder cancer by bioinformatics and machine learning.
    Front Immunol. 2024;15:1465638.
    PubMed    
    Abstract available
    
    

25. TIAN T, He S, Hao H, Guan B, et al
    YWHAG promotes bladder cancer metastasis by regulating TMOD3 to activate ERK1/2 and JNK phosphorylation in the MAPK pathway.
    J Transl Med. 2024;22:1159.
    PubMed    
    Abstract available
    
    

26. HUANG X, Sun C, Zhang P, Wang L, et al
    Programmed cell death 1 inhibitor alone or combined with chemotherapy for patients with locally advanced or metastatic urothelial carcinoma: a single-center experience.
    BMC Urol. 2024;24:289.
    PubMed    
    Abstract available
    
    

27. HAN JH, Yuk HD, Jeong SH, Jeong CW, et al
    Anesthetic approaches and 2-year recurrence rates in non-muscle invasive bladder cancer: a randomized clinical trial.
    Reg Anesth Pain Med. 2024 Dec 31:rapm-2024-105949. doi: 10.1136/rapm-2024-105949
    PubMed    
    Abstract available
    
    

28. LIN J, Jiang S, Chen B, Du Y, et al
    Tertiary Lymphoid Structures are Linked to Enhanced Antitumor Immunity and Better Prognosis in Muscle-Invasive Bladder Cancer.
    Adv Sci (Weinh). 2024 Dec 30:e2410998. doi: 10.1002/advs.202410998.
    PubMed    
    Abstract available
    
    

29. SIDDIQUE MFH, Uddin MM, Salam MA, Rahman MS, et al
    Causes and Consequences of Delayed Presentation of Muscle Invasive Urinary Bladder Carcinoma.
    Mymensingh Med J. 2025;34:98-105.
    PubMed    
    Abstract available
    
    

30. ZAURITO P, Scilipoti P, Longoni M, de Angelis M, et al
    Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer.
    World J Urol. 2024;43:52.
    PubMed    
    Abstract available
    
    

31. DEHGHANPOUR A, Pecoraro M, Messina E, Laschena L, et al
    Diagnostic accuracy and inter-reader agreement of the nacVI-RADS for bladder cancer treated with neoadjuvant chemotherapy: a prospective validation study.
    Eur Radiol. 2024 Dec 31. doi: 10.1007/s00330-024-11327.
    PubMed    
    Abstract available
    
    

32. BANNIER PA, Saillard C, Mann P, Touzot M, et al
    AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer.
    Nat Commun. 2024;15:10914.
    PubMed    
    Abstract available
    
    

33. JIANG X, Qu A, Zhang S, Jin S, et al
    RNA-seq profiling identified a three-lncRNA panel in serum as potential biomarker for muscle-invasive bladder cancer.
    Front Oncol. 2024;14:1451009.
    PubMed    
    Abstract available
    
    

34. GHAMMEM N, Bischoff H, Chiappa P, Somme L, et al
    Case report: Long-term response to a combination of immune checkpoint inhibitors as a single treatment for multiple synchronous cancers: a case study.
    Front Immunol. 2024;15:1487227.
    PubMed    
    Abstract available
    
    

35. ZHANG Y, Shao X, Ding L, Xia W, et al
    Prognostic value of the triglyceride-glucose index in non-muscle-invasive bladder cancer: a retrospective study.
    Front Nutr. 2024;11:1472104.
    PubMed    
    Abstract available
    
    

36. ZOU XC, Rao XP, Huang JB, Zhou J, et al
    Predicting distant metastasis of bladder cancer using multiple machine learning models: a study based on the SEER database with external validation.
    Front Oncol. 2024;14:1477166.
    PubMed    
    Abstract available
    
    

37. PAN X, Wang P, Gu J, Wang Y, et al
    Improved epirubicin delivery selectivity to bladder cancer achieved by functionalized hydroxyethyl starch-based prodrug.
    Int J Biol Macromol. 2024;293:139275.
    PubMed    
    Abstract available
    
    

38. LUO X, Xie F, Qin G, Zou G, et al
    circICMT upregulates and suppresses the malignant behavior of bladder cancer.
    Transl Oncol. 2024;52:102262.
    PubMed    
    Abstract available
    
    

39. HUANG Z, Liu B, Li X, Jin C, et al
    RUNX2 enhances bladder cancer progression by promoting glutamine metabolism.
    Neoplasia. 2024;60:101120.
    PubMed    
    Abstract available
    
    

40. WU Y, Ying Y, Zhang F, Shu X, et al
    NSUN2-Mediated R-loop Stabilization as a Key Driver of Bladder Cancer Progression and Cisplatin Sensitivity.
    Cancer Lett. 2024 Dec 26:217416. doi: 10.1016/j.canlet.2024.217416.
    PubMed    
    Abstract available
    
    

41. THOMAS J, Jain A, Hirpara R, Blachman-Braun R, et al
    Impact of BMI Category on Recurrence and Progression of Nonmuscle Invasive Bladder Cancer Prognosis.
    Clin Genitourin Cancer. 2024;23:102286.
    PubMed    
    Abstract available
    
    

42. WANG J, Zhang N, Peng M, Hua X, et al
    Corrigendum to "p85alpha Inactivates MMP-2 and Suppresses Bladder Cancer Invasion by Inhibiting MMP-14 Transcription and TIMP-2 Degradation" [Neoplasia (2019) 21, 908-920].
    Neoplasia. 2024;60:101095.
    PubMed    
    
    
    

43. XIAO Y, Ju L, Jin W, Peng H, et al
    Concurrent DNA hypomethylation and epigenomic reprogramming driven by androgen receptor binding in bladder cancer oncogenesis.
    Clin Transl Med. 2025;15:e70153.
    PubMed    
    
    
    

44. DA SILVA IM, Maraslis FT, Kawasaki JAI, Aida NK, et al
    Allelic variants in xenobiotic metabolism genes predict susceptibility and worse prognosis of urothelial bladder cancer.
    Pathol Res Pract. 2024;266:155767.
    PubMed    
    Abstract available
    
    

45. KOKENEK UNAL TD, Aksoy Altinboga A
    A pilot study of the value of micronucleus count in urinary cytology samples in the follow-up of patients with urothelial carcinoma: Implications for diagnosis and prognosis.
    Cancer Cytopathol. 2025;133:e22923.
    PubMed    
    Abstract available
    
    

46. CHUKWUDEBE O, Lynch E, Vira M, Vaickus L, et al
    A review of the performance of urinary cytology with a focus on atypia, upper tract and updates on novel ancillary testing.
    J Am Soc Cytopathol. 2025;14:23-35.
    PubMed    
    Abstract available
    
    

47. POLICARPIO-NICOLAS MLC, McIntire PJ
    Case Series of Thermal Cautery Artifact in Urine Cytology: An Uncommon Finding but a Potential Pitfall.
    Diagn Cytopathol. 2025;53:72-75.
    PubMed    
    Abstract available
    
    

48. KHAIRWA A, Swati, Mahajan P, Diwaker P, et al
    A Comparative Study of the Paris System and Common Reporting System for Urine Cytology With Cyto-Histology Correlation: A Study of 829 Urine Cytology Specimens.
    Diagn Cytopathol. 2025;53:51-57.
    PubMed    
    Abstract available
    
    

49. APOLO AB, Ballman KV, Sonpavde G, Berg S, et al
    Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
    N Engl J Med. 2025;392:45-55.
    PubMed    
    Abstract available
    
    

50. GAO K, Jiang H, Zhang C, Li L, et al
    Suppressing the progression of bladder cancer using cyclovirobuxine D based on network pharmacology and bioinformatics approaches.
    Naunyn Schmiedebergs Arch Pharmacol. 2025.
    PubMed    
    Abstract available
    
    

51. PICHLER R, Thurnher M
    Training the synergy between Bacillus Calmette-Guerin and immune checkpoint-blocking antibodies in bladder cancer.
    Cancer Commun (Lond). 2025 Jan 10. doi: 10.1002/cac2.12647.
    PubMed    
    
    
    

52. YAU STY, Hung CT, Leung EYM, Chong KC, et al
    Point-Based Prediction Model for Bladder Cancer Risk in Diabetes: A Random Survival Forest-Guided Approach.
    J Clin Med. 2024;14:4.
    PubMed    
    Abstract available
    
    

53. HWANG WK, Jo SB, Han DE, Ahn ST, et al
    Artificial Intelligence-Based Classification and Segmentation of Bladder Cancer in Cystoscope Images.
    Cancers (Basel). 2024;17:57.
    PubMed    
    Abstract available
    
    

54. SEVIM NALKIRAN H, Biri I, Nalkiran I, Uzun H, et al
    CDC20 and CCNB1 Overexpression as Prognostic Markers in Bladder Cancer.
    Diagnostics (Basel). 2024;15:59.
    PubMed    
    Abstract available
    
    

55. GONG Y, Gao D, Shi Y, Fan G, et al
    SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway.
    Commun Biol. 2025;8:36.
    PubMed    
    Abstract available
    
    

56. ZHENG Q, Jiao P, Yang R, Fan J, et al
    Deep learning-based lymph node metastasis status predicts prognosis from muscle-invasive bladder cancer histopathology.
    World J Urol. 2025;43:65.
    PubMed    
    Abstract available
    
    

57. PETROV M, Makarova N, Monemian A, Pham J, et al
    Detection of Human Bladder Epithelial Cancerous Cells with Atomic Force Microscopy and Machine Learning.
    Cells. 2024;14:14.
    PubMed    
    Abstract available
    
    

58. REDDY DEPA A, Reddy Beeravalli R, Bommiti A, Pawar S, et al
    Successful Treatment of Non-invasive Bladder Cancer During Pregnancy: Diagnostic and Management Challenges.
    Cureus. 2024;16:e75417.
    PubMed    
    Abstract available
    
    

59. WANG Z, Li S, Zheng F, Xiong S, et al
    Construction and validation of prognosis and treatment outcome models based on plasma membrane tension characteristics in bladder cancer.
    PeerJ. 2025;13:e18816.
    PubMed    
    Abstract available
    
    

60. LI S, Gui J, Karagas MR, Passarelli MN, et al
    Transcriptome-wide association study identifies genes associated with bladder cancer risk.
    Sci Rep. 2025;15:1390.
    PubMed    
    Abstract available
    
    

61. WISE CF, Herkert NJ, Hoffman K, Vaden S, et al
    Environmental Exposures and Canine Bladder Cancer: A Case Control Study Using Silicone Passive Samplers.
    Environ Sci Technol. 2025 Jan 9. doi: 10.1021/acs.est.4c09271.
    PubMed    
    Abstract available
    
    

62. CHUNG CH, Huang IS, Kao WT
    Short-term outcomes after robot-assisted versus open radical cystectomy for bladder cancer in patients with diabetes mellitus: an analysis of the United States Nationwide Inpatient Sample of 2005-2018.
    Int J Med Sci. 2025;22:409-416.
    PubMed    
    Abstract available
    
    

63. ZHAO X, Wang J, Tian S, Tang L, et al
    FKBP10 Promotes the Muscle Invasion of Bladder Cancer via Lamin A Dysregulation.
    Int J Biol Sci. 2025;21:758-771.
    PubMed    
    Abstract available
    
    

64. STEINMETZ AR, Jazayeri B, Pierce M, Mokkapati S, et al
    Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer.
    Expert Opin Biol Ther. 2025 Jan 9:1-11. doi: 10.1080/14712598.2024.2445674.
    PubMed    
    Abstract available
    
    

65. LEI Z, Han Y, Liao J, Li X, et al
    The Role of SWI/SNF Complex in Bladder Cancer.
    J Cell Mol Med. 2025;29:e70348.
    PubMed    
    Abstract available
    
    

66. DEMIRCI A, Uzel T, Bolat A, Basar H, et al
    Do the inflammatory markers have a prognostic role in an elderly patient population diagnosed with non-muscle invasive bladder cancer?
    Cir Cir. 2025 Jan 8. doi: 10.24875/CIRU.23000278.
    PubMed    
    Abstract available
    
    

67. GE Z, Lin S, Lu C, Xia Y, et al
    Panel containing three serum microRNAs: a promising biomarker for early detection of bladder cancer.
    Front Oncol. 2024;14:1470457.
    PubMed    
    Abstract available
    
    

68. LIU Y, Tao H, Jia S, Wang H, et al
    Prognostic value and immune landscapes of disulfidptosis?related lncRNAs in bladder cancer.
    Mol Clin Oncol. 2024;22:19.
    PubMed    
    Abstract available
    
    

69. KHALIL IA, Younes N, Badawi A, Al Rumaihi K, et al
    Efficacy and safety of office-based diode laser ablation for recurrent low-grade non-muscle-invasive bladder cancer under local anaesthesia: A pilot study.
    Arab J Urol. 2024;23:70-74.
    PubMed    
    Abstract available
    
    

70. MILLING RV, Nielsen NK, Graugaard-Jensen C, Christensen P, et al
    Impact of late effects after treatment for bladder cancer with radical cystectomy on Quality of life: a case-control study.
    Acta Oncol. 2025;64:27-33.
    PubMed    
    Abstract available
    
    

71. WU J, Shang BQ, Shou JZ, Wang ZP, et al
    A nomogram for predicting lymph node metastases in nonmetastatic muscle-invasive bladder cancer: a SEER-based investigation.
    Int J Surg. 2025 Jan 8. doi: 10.1097/JS9.0000000000002222.
    PubMed    
    
    
    

72. ZHANG S, Wang Y, Han Z, Lu B, et al
    AL16431.1 is identified as a biomarker for bladder cancer progression and immunotherapy response.
    Sci Rep. 2025;15:1170.
    PubMed    
    Abstract available
    
    

73. YU H, Kim SJ, Bae Y, Kim M, et al
    Sex differences in the risk of bladder cancer among kidney transplant recipients and patients with kidney failure receiving hemodialysis: a nationwide cohort study.
    Am J Nephrol. 2025 Jan 7:1-16. doi: 10.1159/000543298.
    PubMed    
    Abstract available
    
    

74. TORTORA F, Guastaferro A, Barbato S, Febbraio F, et al
    New Challenges in Bladder Cancer Diagnosis: How Biosensing Tools Can Lead to Population Screening Opportunities.
    Sensors (Basel). 2024;24:7873.
    PubMed    
    Abstract available
    
    

75. HONG SH, Cha HJ, Hwang-Bo H, Kim MY, et al
    Correction: Hong et al. Anti-Proliferative and Pro-Apoptotic Effects of Licochalcone A through ROS-Mediated Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells. Int. J. Mol. Sci. 2019, 20, 3820.
    Int J Mol Sci. 2024;25:13595.
    PubMed    
    Abstract available
    
    

76. JUHASZ D, Csizmarik A, Szalontai J, Keszthelyi A, et al
    Precision Oncology Approach for Urachal Carcinoma: A Clinical Case Report.
    Int J Mol Sci. 2024;25:13315.
    PubMed    
    Abstract available
    
    

77. PATWARDHAN MV, Kane TQ, Chiong E, Rahmat JN, et al
    Loss of Glutathione-S-Transferase Theta 2 (GSTT2) Modulates the Tumor Microenvironment and Response to BCG Immunotherapy in a Murine Orthotopic Model of Bladder Cancer.
    Int J Mol Sci. 2024;25:13296.
    PubMed    
    Abstract available
    
    

78. DEGERLI E, Arslan C, Selcukbiricik F, Olmez OF, et al
    Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy.
    Medicina (Kaunas). 2024;60:2103.
    PubMed    
    Abstract available
    
    

79. MYSZKA A, Ciesla M, Siekierzynska A, Sendera A, et al
    Predictive Molecular Biomarkers of Bladder Cancer Identified by Next-Generation Sequencing-Preliminary Data.
    J Clin Med. 2024;13:7701.
    PubMed    
    Abstract available
    
    

80. DO AT, Pham QT, Nguyen NMT, Nguyen PN, et al
    Immunohistochemical Evaluation of Basal and Luminal Markers in Bladder Cancer: A Study from a Single Institution.
    Life (Basel). 2024;14:1670.
    PubMed    
    Abstract available
    
    

81. RICO-MENDEZ MA, Ayala-Madrigal ML, Gonzalez-Mercado A, Gutierrez-Angulo M, et al
    Microsatellite Instability in Urine: Breakthrough Method for Bladder Cancer Identification.
    Biomedicines. 2024;12:2726.
    PubMed    
    Abstract available
    
    

82. LYDOM LN, Lauridsen SV, Joensen UN, Tonnesen H, et al
    The Potential for Lifestyle Intervention Among Patients Undergoing Transurethral Resection of Bladder Tumour Based on Patient Needs Including Smoking and Other Risky Lifestyle Factors: A Cross-Sectional Study.
    Int J Environ Res Public Health. 2024;21:1633.
    PubMed    
    Abstract available
    
    

83. GUDOWSKA-SAWCZUK M, Paczek S, Olkowicz M, Kudelski J, et al
    Gasdermin D (GSDM D) as a Potential Diagnostic Biomarker in Bladder Cancer: New Perspectives in Detection.
    Cancers (Basel). 2024;16:4213.
    PubMed    
    Abstract available
    
    

84. MATLOUBIEH JE, Hanelin D, Agalliu I
    Comparisons of Intravesical Treatments with Mitomycin C, Gemcitabine, and Docetaxel for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: Updated Systematic Review and Meta-Analysis.
    Cancers (Basel). 2024;16:4125.
    PubMed    
    Abstract available
    
    

85. BAI K, Long Y, Yuan F, Huang X, et al
    Hedyotis diffusa injection modulates the ferroptosis in bladder cancer via CAV1/JUN/VEGFA.
    Int Immunopharmacol. 2025;147:113925.
    PubMed    
    Abstract available
    
    

86. YUK HD, Han JH, Jeong SH, Jeong CW, et al
    Beta-human chorionic gonadotropin, carbohydrate antigen 19-9, cancer antigen 125, and carcinoembryonic antigen as prognostic and predictive biological markers in bladder cancer.
    Front Oncol. 2024;14:1479988.
    PubMed    
    Abstract available
    
    

87. TELLI E, Yaprak Bayrak B, Yilmaz H
    Perivascular Epithelioid-Cell Tumour of the Bladder: A Case Report.
    Arch Esp Urol. 2024;77:1211-1215.
    PubMed    
    Abstract available
    
    

88. TACHIBANA A, Moriyasu M, Miyazaki K, Toyoshima Y, et al
    [Efficacy and Adverse Events of Low-Dose Intravesical BCG Therapy for Non-Muscle-Invasive Bladder Cancer].
    Hinyokika Kiyo. 2024;70:445-450.
    PubMed    
    Abstract available
    
    

89. YIN J, Fan X, Chang Q, Dai Y, et al
    The N(1)-methyladenosine methyltransferase TRMT61A promotes bladder cancer progression and is targetable by small molecule compounds.
    Clin Transl Med. 2025;15:e70137.
    PubMed    
    
    
    

90. GONG MZ, He HY
    [Detection and interpretation of PD-L1 in urologic neoplasms].
    Zhonghua Bing Li Xue Za Zhi. 2025;54:11-15.
    PubMed    
    Abstract available
    
    

91. JIN K, Ding Y, Xu J, Liu Z, et al
    Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression.
    J Immunother Cancer. 2025;13:e010964.
    PubMed    
    Abstract available
    
    

92. XIAO JH, Xu LZ, Ning JZ, Cheng F, et al
    Unveiling ADAMTS12: A Key Driver of Bladder Cancer Progression via COL3A1-Mediated Activation of the FAK/PI3K/AKT Signaling Pathway.
    J Biol Chem. 2025 Jan 4:108155. doi: 10.1016/j.jbc.2025.108155.
    PubMed    
    Abstract available
    
    

93. SCHLETTE N, Burton E, Harris A, Langsten K, et al
    Microfilaria in the Urine of a Dog with Concurrent Urinary Bladder Sarcoma.
    J Am Anim Hosp Assoc. 2025;61:12-14.
    PubMed    
    Abstract available
    
    

94. SAKATANI T, Sumiyoshi T, Kita Y, Takada H, et al
    Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer.
    JCO Precis Oncol. 2025;9:e2400472.
    PubMed    
    Abstract available
    
    

95. SEIDEN B, Ajay D, Cheung F, Clements M, et al
    Management of Lower Urinary Tract Symptoms during the Treatment for Non-Muscle Invasive Bladder Cancer.
    Curr Urol Rep. 2025;26:24.
    PubMed    
    Abstract available
    
    

96. FENG C, Wang Y, Song W, Liu T, et al
    Spatially-resolved analyses of muscle invasive bladder cancer microenvironment unveil a distinct fibroblast cluster associated with prognosis.
    Front Immunol. 2024;15:1522582.
    PubMed    
    Abstract available
    
    

97. WU TC, Lin CC
    Passing the Torch forward: Moving beyond EGFR Inhibition in NMIBC Prevention.
    Cancer Prev Res (Phila). 2025;18:7-9.
    PubMed    
    Abstract available
    
    

98. ECKE TH, Styrke J, Jagarlamudi K, Linder S, et al
    Development of point-of-care tests for urinary bladder cancer - an historic review and view to future prospectives.
    Urol Oncol. 2025 Jan 4:S1078-1439(24)01043-3. doi: 10.1016/j.urolonc.2024.
    PubMed    
    Abstract available
    
    

99. SHINOHARA Y, Elbadawy M, Liu Y, Yamanaka M, et al
    Anticancer potentialsof chaga and notoginseng against dog bladder cancer organoids.
    J Vet Med Sci. 2025 Jan 3. doi: 10.1292/jvms.24-0258.
    PubMed    
    Abstract available
    
    

100. LV J, Zhang Y, Wu Q, Jiang P, et al
     Inhibition of SIRT4 promotes bladder cancer progression and immune escape via attenuating CD8(+) T cells function.
     Int Immunopharmacol. 2025;147:113906.
     PubMed    
     Abstract available
     
     

101. VEIL C, Krauss F, Amend B, Fend F, et al
     Electrical impedance-based tissue classification for bladder tumor differentiation.
     Sci Rep. 2025;15:825.
     PubMed    
     Abstract available
     
     

102. LYONS MS, Baker C, Chaput G, Finelli A, et al
     Preferred labels and language to improve communication about lesions at low risk of progressing to cancer: qualitative interviews with patients and physicians.
     BMJ Open. 2025;15:e087484.
     PubMed    
     Abstract available
     
     

103. SERPELONI JM, Silva IMD, van Helvoort Lengert A, de Souza MF, et al
     Genetic polymorphisms, methylation, and expression levels in the GSTP1 and MGMT genes in urothelial bladder tumors.
     Gene. 2025;939:149158.
     PubMed    
     Abstract available
     
     

104. SONG Y, Du Y, Jiang S, Peng Y, et al
     Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma.
     Pharmacol Res. 2025;211:107543.
     PubMed    
     Abstract available
     
     

105. WANG M, Chen W, Li M, Lin F, et al
     TE-RPA: One-tube telomerase extension recombinase polymerase amplification-based electrochemical biosensor for precise diagnosis of urothelial carcinoma.
     Biosens Bioelectron. 2025;271:117042.
     PubMed    
     Abstract available
     
     

106. HERNANDEZ-PRAT A, Rodriguez-Vida A, Cardona L, Qin M, et al
     Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors.
     Mol Oncol. 2025;19:151-172.
     PubMed    
     Abstract available
     
     

107. APOLO AB, Michaels-Igbokwe C, Simon NI, Benjamin DJ, et al
     Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding.
     Patient. 2025;18:77-87.
     PubMed    
     Abstract available
     
     

108. SHKOLYAR E, Zhou SR, Carlson CJ, Chang S, et al
     Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence.
     Nat Rev Urol. 2025;22:46-54.
     PubMed    
     Abstract available
     
     

109. WANG X, Li S, Li Z, Lin Z, et al
     SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase.
     Lipids Health Dis. 2025;24:14.
     PubMed    
     Abstract available
     
     

110. STOOF J, Kalmoua Z, Sobota A, Brakenhoff RH, et al
     Non-thermal plasma as promising anti-cancer therapy against bladder cancer by inducing DNA damage and cell cycle arrest.
     Sci Rep. 2025;15:2334.
     PubMed    
     Abstract available
     
     

111. HIYAMA Y, Shindo T, Takahashi A, Fukuta F, et al
     The incidence and risk factor for febrile urinary tract infection after robot-assisted laparoscopic radical cystectomy in bladder cancer patients.
     J Infect Chemother. 2025 Jan 15:102624. doi: 10.1016/j.jiac.2025.102624.
     PubMed    
     Abstract available
     
     

112. EL SAFTAWY EA, Aboulhoda BE, AbdElkhalek MA, Alghamdi MA, et al
     Non-coding RNAs in urinary bladder cancer microenvironment: Diagnostic, therapeutic, and prognostic perspective.
     Pathol Res Pract. 2025;266:155815.
     PubMed    
     Abstract available
     
     

113. YANG F, Guo Z, Wu J, Lu X, et al
     Circ-ITCH inhibits bladder cancer progression through miR-184/FOXO3 axis.
     Am J Transl Res. 2024;16:7911-7923.
     PubMed    
     Abstract available
     
     

114. MIZUNO R, Maekawa H, Hida K, Goto T, et al
     Robotic Laparoscopy and Endoscopy Cooperative Surgery for Primary Appendiceal Mucinous Carcinoma Masquerading as Bladder Cancer: A Case Report.
     Asian J Endosc Surg. 2025;18:e70021.
     PubMed    
     Abstract available
     
     

115. ZHU C, Lin L, Huang C, Li Z, et al
     Circ-NMNAT1 Drives Tumor Progression in Bladder Cancer by Modulating the miR-370-3p/ATXN2L Axis.
     Appl Biochem Biotechnol. 2025 Jan 16. doi: 10.1007/s12010-024-05162.
     PubMed    
     Abstract available
     
     

116. AJAMI T, Musquera M, Palou J, Guru KA, et al
     A multicenter study of perioperative and functional outcomes of open vs. robot assisted uretero-enteric reimplantation after radical cystectomy.
     World J Urol. 2025;43:74.
     PubMed    
     Abstract available
     
     

117. FANG F, Wu T, Wang M, Li W, et al
     Matrix Metalloproteinase-9 is associated with tumor microenvironment remodeling of bladder cancer.
     Biol Direct. 2025;20:8.
     PubMed    
     Abstract available
     
     

118. DANESHMAND S, Kamat AM, Shore ND, Meeks JJ, et al
     Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
     Urol Oncol. 2025 Jan 15:S1078-1439(24)01044.
     PubMed    
     Abstract available
     
     

119. HAN S, Li Y, Chen D, Si Z, et al
     Comprehensive Genetic Profile of Chinese Muscle-Invasive Bladder Cancer Cohort.
     Clin Genitourin Cancer. 2024;23:102280.
     PubMed    
     Abstract available
     
     

120. OLAH C, Shmorhun O, Klamminger GG, Rawitzer J, et al
     Immunohistochemistry-based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy.
     J Pathol Clin Res. 2025;11:e70017.
     PubMed    
     Abstract available
     
     

121. SUN N, Zhang Z, Yang X, Li J, et al
     Unveiling urinary extracellular vesicle mRNA signature for early diagnosis and prognosis of bladder cancer.
     Theranostics. 2025;15:1272-1284.
     PubMed    
     Abstract available
     
     

122. WEDHOLM A, Wiberg E, Styrke J, Liden O, et al
     Validation of clinical T stages and of prognostic negative markers in patients with muscle invasive bladder cancer: data in the Swedish National Bladder Cancer Registry vs. data from a detailed research database.
     Transl Androl Urol. 2024;13:2757-2770.
     PubMed    
     Abstract available
     
     

123. WANG J, Zheng Q, Jian J, Chen Z, et al
     Construction of a disulfidptosis-associated lncRNA signature to predict prognosis in bladder cancer.
     Transl Androl Urol. 2024;13:2705-2723.
     PubMed    
     Abstract available
     
     

124. HENDRI AZ, Suryawati S, Heriyanto DS, Hardianti MS, et al
     Long non-coding RNAs as prognostic biomarkers in non-muscle invasive bladder cancer: A systematic review.
     Narra J. 2024;4:e1233.
     PubMed    
     Abstract available
     
     

125. SETIANINGSIH YA, Djatisoesanto W, Laksita TB, Aryati A, et al
     Diagnostic accuracy of urinary cytokeratin fragment-19 (CYFRA21-1) for bladder cancer.
     Narra J. 2024;4:e1142.
     PubMed    
     Abstract available
     
     

126. SHARMA G, Shergill K, Patil M, Radcliffe R, et al
     Neuroendocrine tumour of the urinary bladder.
     BMJ Case Rep. 2025;18:e263265.
     PubMed    
     Abstract available
     
     

127. MOKKAPATI S, Manyam G, Steinmetz AR, Tholomier C, et al
     Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery.
     Transl Oncol. 2025;52:102269.
     PubMed    
     Abstract available
     
     

128. YAMASHITA R, Sugino T, Notsu A, Ito K, et al
     Clinical outcome of BCG treatment for patients with urothelial carcinoma of the prostatic urethra: Implications for early cystectomy.
     World J Urol. 2025;43:71.
     PubMed    
     Abstract available
     
     

129. WANG X, Lee D, Xu H, Sui Y, et al
     PIN1 prolyl isomerase promotes initiation and progression of bladder cancer through the SREBP2-mediated cholesterol biosynthesis pathway.
     Cancer Discov. 2025 Jan 14. doi: 10.1158/2159-8290.CD-24-0866.
     PubMed    
     Abstract available
     
     

130. WANG N, Pachai MR, Li D, Lee CJ, et al
     Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters.
     Nat Genet. 2025;57:165-179.
     PubMed    
     Abstract available
     
     

131. WANG J, Li X, Zhao L, Fan X, et al
     The MCM6-c-Myc positive feedback loop mediates bladder cancer progression and cisplatin resistance.
     Int J Biol Macromol. 2025;296:139777.
     PubMed    
     Abstract available
     
     

132. KHANDAKAR H, Kaushal S, Seth A, Sahoo RK, et al
     Comparative evaluation of PD-L1 expression and tumor immune microenvironment in molecular subtypes of muscle-invasive bladder cancer and its correlation with survival outcomes.
     Am J Clin Pathol. 2025 Jan 13:aqae176. doi: 10.1093.
     PubMed    
     Abstract available
     
     

133. ABAZARI O, Shahidi M, Dayati P, Valizadeh S, et al
     Study of urine-based mRNA biomarkers for early detection of nonmuscle invasive bladder cancer (NMIBC).
     Urol Oncol. 2025 Jan 11:S1078-1439(24)01050.
     PubMed    
     Abstract available
     
     

134. WANG Q, Zhao L
     [Impacts of curcumin on proliferation, migration and cisplatin resistance of bladder cancer cells by regulating LKB1-AMPK-LC3 signaling pathway].
     Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2025;41:9-16.
     PubMed    
     Abstract available
     
     

135. CHANG G, Weijie Z, Jinying H, Bingzhang Q, et al
     Research progress of near-infrared fluorescence imaging in accurate theranostics in bladder cancer.
     Photodiagnosis Photodyn Ther. 2025 Jan 9:104480.
     PubMed    
     Abstract available
     
     

136. ONISHI T, Shibahara T, Sekito S, Kato M, et al
     Feasibility and Oncological Outcome of Patients Achieving Noninvasive Downstaging After Transurethral Resection of Bladder Tumor Plus Systemic Chemotherapy for Bladder Preservation Strategy in Muscle-Invasive Bladder Cancer.
     Clin Genitourin Cancer. 2024;23:102290.
     PubMed    
     Abstract available
     
     

137. RETZ M, Grimm MO, Leucht K, Zschabitz S, et al
     [Enfortumab vedotin and pembrolizumab : Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma].
     Urologie. 2025;64:60-74.
     PubMed    
     Abstract available
     
     

138. SONG L, Xue F, Li T, Zhang Q, et al
     Differential Diagnosis of Urinary Cancers by Surface-Enhanced Raman Spectroscopy and Machine Learning.
     Anal Chem. 2025;97:27-32.
     PubMed    
     Abstract available
     
     

139. WU Q, Lv J, Li X
     Membrane palmitoylated protein MPP1 inhibits immune escape by regulating the USP12/ CCL5 axis in urothelial carcinoma.
     Int Immunopharmacol. 2025;146:113802.
     PubMed    
     Abstract available
     
     

140. TAGLIERO LE, Jones TL, Sherman CE, Aziz KT, et al
     Upper Extremity Mass as First Presentation of Metastatic Urothelial Carcinoma.
     Orthopedics. 2025;48:e52-e55.
     PubMed    
     Abstract available
     
     

141. ISOBE T, Naiki T, Sugiyama Y, Naiki-Ito A, et al
     Experience and Prognostic Analysis with Avelumab Switch Maintenance Treatment in Metastatic Urothelial Carcinoma.
     Oncology. 2025;103:11-21.
     PubMed    
     Abstract available
     
     

142. KASINSKI D, Szeliski K, Drewa T, Pokrywczynska M, et al
     Extracellular vesicles-a new player in the development of urinary bladder cancer.
     Ther Adv Med Oncol. 2025;17:17588359241297529.
     PubMed    
     Abstract available
     
     

143. MATSUKAWA A, Yanagisawa T, Miszczyk M, Parizi MK, et al
     Incidence and Outcomes of Secondary Bladder Cancer Following Radiation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
     Eur Urol Focus. 2025 Jan 22:S2405-4569(24)00262.
     PubMed    
     Abstract available
     
     

144. KEENAN RA
     Roadmap for the transition to robotic radial cystectomy for patients with bladder cancer in a tertiary urology unit: planning for change.
     BMJ Lead. 2025 Jan 22:leader-2024-001044. doi: 10.1136/leader-2024-001044.
     PubMed    
     Abstract available
     
     

145. KNOWLTON SE, Wardell AC, Smith A, Bjurlin M, et al
     Association of Prehabilitation in the Precystectomy Pathway in Patients With Bladder Cancer on Postoperative Outcomes.
     Clin Genitourin Cancer. 2024;23:102297.
     PubMed    
     Abstract available
     
     

146. AKRAMI R, Hadji M, Rashidian H, Nazemipour M, et al
     Interaction between opium use and cigarette smoking on bladder cancer: An inverse probability weighting approach based on a multicenter case-control study in Iran.
     Glob Epidemiol. 2024;9:100182.
     PubMed    
     Abstract available
     
     

147. SORDELLI F, Desai A, Dagnino F, Contieri R, et al
     Xpert Bladder Cancer Detection in Emergency Setting Assessment (XESA Project): A Prospective, Single-centre Trial.
     Eur Urol Open Sci. 2024;71:172-179.
     PubMed    
     Abstract available
     
     

148. MONARDO R, Arif S, Rege A, Simon E, et al
     Bacillus Calmette-Guerin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol.
     Syst Rev. 2025;14:21.
     PubMed    
     Abstract available
     
     

149. MESA N, Perez S, Rodriguez L, Rodriguez P, et al
     Ethnicity and race as modifiers of the association between patient sex and stage at diagnosis of bladder cancer.
     Cancer Epidemiol. 2025;95:102749.
     PubMed    
     Abstract available
     
     

150. CABON S, Brihi S, Fezzani R, Pierre-Jean M, et al
     Combining a Risk Factor Score Designed From Electronic Health Records With a Digital Cytology Image Scoring System to Improve Bladder Cancer Detection: Proof-of-Concept Study.
     J Med Internet Res. 2025;27:e56946.
     PubMed    
     Abstract available
     
     

151. MEIRSON T, Ofer J, Zimhony-Nissim N, Bareket-Samish A, et al
     Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.
     JAMA Netw Open. 2025;8:e2455630.
     PubMed    
     Abstract available
     
     

152. LI J, Shan K, Huang W, Su Q, et al
     The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer.
     Front Immunol. 2025;15:1432586.
     PubMed    
     Abstract available
     
     

153. ABBAS S, Shafik R, Soomro N, Heer R, et al
     AI predicting recurrence in non-muscle-invasive bladder cancer: systematic review with study strengths and weaknesses.
     Front Oncol. 2025;14:1509362.
     PubMed    
     Abstract available
     
     

154. KHAN A, Wang S, Barry KH, Onukwugha E, et al
     Impact of race-based calculations of eGFR on the management of muscle invasive bladder cancer.
     Am J Clin Exp Urol. 2024;12:389-398.
     PubMed    
     Abstract available
     
     

155. LIU J, Wang L, Peng Y, Long S, et al
     A novel therapeutic strategy utilizing EpCAM aptamer-conjugated gemcitabine for targeting bladder cancer and cancer stem cells.
     Biomater Sci. 2025 Jan 21. doi: 10.1039/d4bm01471.
     PubMed    
     Abstract available
     
     

156. HE J, Dong C, Song X, Qiu Z, et al
     Methyltransferase-like 7B participates in bladder cancer via ACSL3 m(6)A modification in a ferroptosis manner.
     Biol Direct. 2025;20:9.
     PubMed    
     Abstract available
     
     

157. PAPALIA R, Prata F, Tedesco F, Ragusa A, et al
     "Delta" Delta neobladder: a novel stentless simplified totally intracorporeal robotic technique.
     Minerva Urol Nephrol. 2024;76:773-781.
     PubMed    
     Abstract available
     
     

158. MUSHTAQ R, Samad S, Raza A, Raiz A, et al
     Blue light cystoscopy- as an improvised diagnostic modality for bladder tumours.
     J Pak Med Assoc. 2025;75:84-90.
     PubMed    
     Abstract available
     
     

159. SUGIMURA R, Tabei T, Karibe Y, Mitomi T, et al
     [SUCCESSFUL TREATMENT WITH mFOLFOX6 FOR URACHAL ADENOCARCINOMA WITH MULTIPLE LUNG METASTASIS: A CASE REPORT].
     Nihon Hinyokika Gakkai Zasshi. 2024;115:28-32.
     PubMed    
     Abstract available
     
     

160. NISHIHARA K, Kurose H, Ito N, Ohnishi S, et al
     [EFFICACY AND SAFETY OF ENFORTUMAB VEDOTIN IN ADVANCED UROTHELIAL CARCINOMA TREATMENT: AN INITIAL EXPERIENCE IN A SINGLE INSTITUTION].
     Nihon Hinyokika Gakkai Zasshi. 2024;115:21-27.
     PubMed    
     Abstract available
     
     

161. SONKUSARE S, Sampige Prasannakumar S, Ahuja V, Kumar R, et al
     Unusual recurrence in advanced ovarian cancer after interval cytoreductive surgery and HIPEC.
     BMJ Case Rep. 2025;18:e262137.
     PubMed    
     Abstract available
     
     

162. JIA K, Huang S, Wang Z, Lin Y, et al
     Utilizing vaginal natural orifice to facilitate bowel manipulation during totally intracorporeal ileal conduit construction: a retrospective cohort study.
     Ann Med. 2025;57:2453827.
     PubMed    
     Abstract available
     
     

163. TALUKDER R, Bakaloudi DR, Makrakis D, Diamantopoulos LN, et al
     Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
     Clin Genitourin Cancer. 2025;23:102284.
     PubMed    
     Abstract available
     
     

164. MAMEDE I, Silva C, Alves AC, Oliveira JP, et al
     Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Cancer: An Updated Meta-Analysis of Randomized Controlled Trials.
     Clin Genitourin Cancer. 2025;23:102288.
     PubMed    
     Abstract available
     
     

165. GRASSI P, Hilgers W, Boissier R, Bertucci A, et al
     A French Multicenter Real-Life Study on the Biological and Clinical Parameters Associated With Response to Immune Checkpoint Inhibitors (ICIs) in Second-Line Treatment of Advanced Urothelial Carcinoma: Impact of Antibiotics Administration at the Time
     Clin Genitourin Cancer. 2025;23:102283.
     PubMed    
     Abstract available
     
     

166. GAMVROULAS E, Bailey E, Harrington E, Jones E, et al
     Evaluation of Gemcitabine and Carboplatin Dosing in Patients With Cisplatin-Ineligible Metastatic Urothelial Carcinoma.
     Clin Genitourin Cancer. 2025;23:102279.
     PubMed    
     Abstract available
     
     

167. NIEDERSUESS-BEKE D, Mayrhofer K, Krauter J, Schnabel S, et al
     Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study.
     Clin Genitourin Cancer. 2025;23:102278.
     PubMed    
     Abstract available
     
     

168. MORGANS AK, Sonpavde GP, Shih V, Wright P, et al
     Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab.
     Clin Genitourin Cancer. 2025;23:102270.
     PubMed    
     Abstract available
     
     

169. YIN P, Wei C, Brozovic A, Wu C, et al
     Chitosan/polyvinyl alcohol-based magnetic hydrogel microspheres with controlled retention and regulated drug release for intravesical instillation.
     Int J Biol Macromol. 2025;287:138412.
     PubMed    
     Abstract available
     
     

170. POWLES T, Csoszi T, Loriot Y, Matsubara N, et al
     Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.
     Clin Genitourin Cancer. 2025;23:102261.
     PubMed    
     Abstract available
     
     

171. DE LIMA RD, de Almeida LS, Filho ELM, Mota JM, et al
     Robot-Assisted Cystectomy in Patients With Previous Pelvic Irradiation: A Comprehensive Systematic Review and Single-Arm Meta-Analysis.
     Clin Genitourin Cancer. 2025;23:102259.
     PubMed    
     Abstract available
     
     

172. MAMTANI R, Matsubara N, Pino AM, Herranz UA, et al
     Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial.
     Clin Genitourin Cancer. 2025;23:102248.
     PubMed    
     Abstract available
     
     

173. JIAN Y, Zhang N, Bi Y, Liu X, et al
     TC-Sniffer: A Transformer-CNN Bibranch Framework Leveraging Auxiliary VOCs for Few-Shot UBC Diagnosis via Electronic Noses.
     ACS Sens. 2025;10:213-224.
     PubMed    
     Abstract available
     
     

174. SCILIPOTI P, Longoni M, de Angelis M, Zaurito P, et al
     Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results.
     BJU Int. 2025 Jan 11. doi: 10.1111/bju.16645.
     PubMed    
     Abstract available
     
     

175. KLUGER N, van der van der Bent SAS
     Tattoos as a risk factor for bladder cancer: a call for cohort studies.
     BJU Int. 2025 Jan 14. doi: 10.1111/bju.16648.
     PubMed    
     
     
     

176. OLAH C, Sichward L, Hadaschik B, Darr C, et al
     Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer.
     BJU Int. 2025 Jan 13. doi: 10.1111/bju.16643.
     PubMed    
     Abstract available
     
     

177. O'DONNELL PH, Loriot Y, Csoszi T, Matsubara N, et al
     Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011.
     Cancer. 2025;131:e35601.
     PubMed    
     Abstract available
     
     

178. QIE Y, Huang S, Shen C, Wu Z, et al
     Phase 2 pilot trial of tislelizumab plus low-dose nab-paclitaxel for extensive very high-risk non-muscle-invasive bladder cancer.
     Clin Cancer Res. 2025 Jan 7. doi: 10.1158/1078-0432.CCR-24-3321.
     PubMed    
     Abstract available
     
     

179. CADENAR A, Mancon S, Shariat SF, D'Andrea D, et al
     Is there a role for neoadjuvant therapies followed by radical cystectomy in oligometastatic bladder cancer?
     Curr Opin Urol. 2025 Jan 17. doi: 10.1097/MOU.0000000000001261.
     PubMed    
     Abstract available
     
     

180. SCILIPOTI P, Moschini M, Li R, Lerner SP, et al
     The Financial Burden of Localized and Metastatic Bladder Cancer.
     Eur Urol. 2024 Dec 26:S0302-2838(24)02744-1. doi: 10.1016/j.eururo.2024.
     PubMed    
     Abstract available
     
     

181. DAVIS LE, Calaway A, Shoag J
     Re: Robert Huddart, Shaista Hafeez, Clare Griffin, et al. Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomized Controlled Trial. Eur Urol 2025;87:60-70.
     Eur Urol. 2025 Jan 21:S0302-2838(25)00007-7. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     

182. MASSON-LECOMTE A
     Bladder Cancer Recurrence Following Management of Upper Tract Urothelial Carcinoma: Balancing Prevention and Iatrogenicity.
     Eur Urol. 2025 Jan 21:S0302-2838(25)00015-6. doi: 10.1016/j.eururo.2025.
     PubMed    
     
     
     

183. FRAGKOULIS C, Bamias A, Gavalas N, Tzannis K, et al
     Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group.
     Eur Urol. 2025 Jan 17:S0302-2838(24)02785-4. doi: 10.1016/j.eururo.2024.
     PubMed    
     Abstract available
     
     

184. SUZUKI C, Minagawa T, Onuma H, Hiragata S, et al
     alpha(1)-Blockers as a risk factor for hypotension in combination with oral 5-aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer.
     Int J Urol. 2025 Jan 3. doi: 10.1111/iju.15655.
     PubMed    
     
     
     

185. AKDAS EM, Culha MM, Telli E, Bosnali E, et al
     The effect of intravesical chemohyperthermia with mitomycin in non-muscle-invasive bladder tumour patients who cannot tolerate BCG treatment or recur after treatment and refuse cystectomy.
     Int Urol Nephrol. 2025;57:63-69.
     PubMed    
     Abstract available
     
     

186. ZHAO L, Tian G, Wang X, Li L, et al
     Clinical significance of a new early diagnostic model for bladder cancer based on genome-wide microarray profiling of serum exosomal lncRNAs.
     Int Urol Nephrol. 2025 Jan 7. doi: 10.1007/s11255-024-04360.
     PubMed    
     Abstract available
     
     

187. BRYAN RT, Liu W, Pirrie SJ, Amir R, et al
     Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.
     J Clin Oncol. 2025 Jan 14:JCO2302398. doi: 10.1200/JCO.23.02398.
     PubMed    
     Abstract available
     
     

188. SHARMA V, Fadel A, Tollefson MK, Psutka SP, et al
     Artificial Intelligence-Based Assessment of Preoperative Body Composition Is Associated With Early Complications After Radical Cystectomy.
     J Urol. 2025;213:228-237.
     PubMed    
     Abstract available
     
     

189. TRIPATHY R, Kumar L, Agarwal S, Thakur A, et al
     A comparison between intravesical gemcitabine plus docetaxel and intravesical BCG in the treatment of non-muscle invasive naive urinary bladder cancer: A systematic review and meta-analysis of oncological outcomes.
     Urology. 2025 Jan 9:S0090-4295(25)00006-8. doi: 10.1016/j.urology.2025.
     PubMed    
     Abstract available
     
     

190. CHEN T, Zou X, Li Y, Peng L, et al
     Evaluation of the association between lymph node ratio and long-term survival in patients after surgery for lymph node-positive bladder cancer: a SEER population-based study with external validation.
     BMC Cancer. 2025;25:135.
     PubMed    
     Abstract available